Among the three FDA-approved treatments, SPINRAZA and ZOLGENSMA are leading the market, with SPINRAZA securing a notable ...

Long before there was Sarepta's gene therapy for muscular dystrophy, there was Donavon Decker and his offer to test a gene ...

For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits ...

The Phase II RAINBOWFISH study found that infants treated with Evrysdi (risdiplam) within six weeks of birth reached major ...

“Spinal Muscular Atrophy Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal ...

This week, we hear from brothers Derek and Justin. Justin lives with SMA type 1, and Derek—his brother and caregiver—has ...

HOUSTON – A newly identified gene, atrogin-1, is involved in muscle loss associated with cancer, diabetes, fasting and kidney disease as well as in the atrophy occurring with disuse, inactivity ...

When a person is in a weightless environment for an extended period, their muscles degrade due to lack of use. This phenomenon can also occur in organisms with short life cycles, such as a tiny worm ...